SK, Janssen Korea to co-market Mvix

Published: 2009-10-08 06:56:00

Updated: 2009-10-08 06:56:00

SK Chemicals and Janssen Korea has recently announced that the two companies signed an agreement to co-market Mvix, a new impotence drug, here from the latter half of next year.

MVIX is the 13th new drug developed by the Korean company. SK spent 15 billion won on creating the drug in partnersh...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK